|
|||||
|
|
Liver toxicity of chemotherapy and targeted therapy for breast cancer patients with hepatitis virus infection |
|
| Institution: | 1. Department of Thyroid and Breast Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510000, China;2. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510000, China;1. Division of Surgery Gastroenterological Center, Medico Shunju Shiroyama Hospital, Osaka, Japan;2. Division of Surgery Osaka Medical college, Osaka, Japan;3. Division of Pathology Osaka Medical college, Osaka, Japan;1. State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, China;2. Department of Pathogen Biology and Immunology, Guangdong Pharmaceutical University, Guangzhou 510006, China;1. National Cancer Centre Singapore, Singapore;2. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;3. Hospital Universitario 12 De Octubre, Madrid, Spain;4. Massachusetts General Hospital, Boston, MA, USA;5. Netherlands Cancer Institute, Amsterdam, the Netherlands;6. National Taiwan University Cancer Center, Taipei, Taiwan;7. Aichi Cancer Center, Nagoya, Japan;8. Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;9. Vall d''Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain;10. Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany;11. Evangelische Lungenklinik Berlin, Berlin, Germany;12. Princess Margaret Cancer Centre, Toronto, Ontario, Canada;13. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA;14. Novartis Institutes for BioMedical Research, East Hanover, NJ, USA;15. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;p. Novartis Pharma AG, Basel, Switzerland;q. Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea;1. Department of Urology and Paediatric Urology, Saarland University, Homburg, Germany;2. Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany;1. Department of Surgery, Dalhousie University, 849-1276 South Park Street Street, Halifax, NS, B3H 2Y9, Canada;2. Surgical Oncology, BC Cancer Agency (SAH-CSI), 399 Royal Avenue, Kelowna, BC, V1Y 5L3, Canada;3. Surgical Oncology Network, Canada;4. Department of Surgery, University of British Columbia, Canada;5. BC Cancer Agency, 801 – 686 West Broadway, Vancouver, BC, V5Z 1G1, Canada;6. British Columbia Cancer Agency Research Centre, 703-686 West Broadway, Vancouver, BC, V5Z 1G1, Canada |
| Abstract: | BackgroundChemotherapy has greatly improved the prognosis of breast cancer patients. However, it may also result in undesirable side effects such as hepatitis virus reactivation. Little information is available on the liver toxicity of chemotherapy and targeted therapy for breast cancer patients with hepatitis virus (HBV/HCV) infection.MethodsWe performed a retrospective survey of 835 patients diagnosed with breast cancer between January 2010 and December 2015 at our institution. All patients had been screened for HBV/HCV infection at the time of breast cancer diagnosis. We retrospectively investigated the toxicity of chemotherapy and the changes in HBV/HCV load based on a medical record review.Results52 patients with positive anti-HBV antibody test and 21 patients with positive anti-HCV antibody tests received chemotherapy. 762 patients without HBV and HCV infection served as the control group. The morbidity of liver toxicity and disruptions in chemotherapy attributable to liver toxicity were not significantly different among control group, HBV group and HCV groups (27.7% vs 34.6% vs 42.9%, P = 0.189 and 5.0% vs 9.6% vs 9.5%, P = 0.173, respectively). No patients presented with HBV/HCV reactivation.ConclusionBreast cancer patients with HCV can be treated with chemotherapy and targeted therapy with trastuzumab. Breast cancer patients with HBV who accept antiviral therapy can be treated with chemotherapy and targeted therapy with trastuzumab and patients can benefit from prophylactic antiviral therapy before chemotherapy. However, a multidisciplinary cooperation and closely monitoring liver function during the course of chemotherapy may benefit patients. |
| Keywords: | Hepatitis B virus (HBV) Hepatitis C virus (HCV) Breast cancer Chemotherapy HBV/HCV reactivation Toxicity HCV"} {"#name":"keyword" "$":{"id":"kwrd0045"} "$$":[{"#name":"text" "_":"hepatitis C virus CHC"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"chronic hepatitis C HBV"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"hepatitis B virus CHB"} {"#name":"keyword" "$":{"id":"kwrd1055"} "$$":[{"#name":"text" "_":"chronic hepatitis B DAAs"} {"#name":"keyword" "$":{"id":"kwrd0075"} "$$":[{"#name":"text" "_":"direct-acting antiviral agents ER"} {"#name":"keyword" "$":{"id":"kwrd0085"} "$$":[{"#name":"text" "_":"estrogen receptor PR"} {"#name":"keyword" "$":{"id":"kwrd0095"} "$$":[{"#name":"text" "_":"progesterone receptor HER-2"} {"#name":"keyword" "$":{"id":"kwrd0105"} "$$":[{"#name":"text" "_":"human epidermal growth factor receptor 2 HBsAg"} {"#name":"keyword" "$":{"id":"kwrd2055"} "$$":[{"#name":"text" "_":"hepatitis B surface antigen AST"} {"#name":"keyword" "$":{"id":"kwrd0115"} "$$":[{"#name":"text" "_":"aspartate aminotransferase ALT"} {"#name":"keyword" "$":{"id":"kwrd0125"} "$$":[{"#name":"text" "_":"alanine aminotransferase TBIL"} {"#name":"keyword" "$":{"id":"kwrd0135"} "$$":[{"#name":"text" "_":"total bilirubin PT"} {"#name":"keyword" "$":{"id":"kwrd0145"} "$$":[{"#name":"text" "_":"prothrombin time CTCAE"} {"#name":"keyword" "$":{"id":"kwrd3055"} "$$":[{"#name":"text" "_":"Common Terminology Criteria For Adverse Events ADL"} {"#name":"keyword" "$":{"id":"kwrd4055"} "$$":[{"#name":"text" "_":"activities of daily living |
| 本文献已被 ScienceDirect 等数据库收录！ | |